Literature DB >> 15138457

BRCA1/2 predictive testing: a study of uptake in two centres.

Lucy Brooks1, Fiona Lennard, Andrew Shenton, Fiona Lalloo, Ingrid Ambus, Audrey Ardern-Jones, Rachel Belk, Bronwyn Kerr, David Craufurd, Rosalind Eeles, D Gareth Evans.   

Abstract

Differences in reported uptake of genetic testing for mutations in BRCA1 and BRCA2 can largely be accounted for by different methodologies and by studying research vs nonresearch families. In our joint study of 75 nonresearch families from two UK centres in which at least 3 years had elapsed since the initial proband had been informed of the availability of testing, only 45 and 34% of eligible individuals from Manchester and London, respectively, had come forward for counselling. Final uptake rates using a non-proactive approach were 53 and 29% for women and 11-12% for men, but the figure among those attending clinic was 73 and 62%, respectively. Unlike previous studies, we did not find that uptake had stabilised after a year with 25% of those being tested more than 2 years after the family was informed, and several delaying a considerable time between genetics appointments. We believe that the particularly low uptake even of counselling in men may need to be addressed by improving family communication or providing information sheets for family members to disseminate.

Entities:  

Mesh:

Year:  2004        PMID: 15138457     DOI: 10.1038/sj.ejhg.5201206

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  19 in total

1.  Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder.

Authors:  G K Suthers; J Armstrong; J McCormack; D Trott
Journal:  J Med Genet       Date:  2005-12-21       Impact factor: 6.318

2.  Increasing utilization of cancer genetic counseling services using a patient navigator model.

Authors:  Alanna Kulchak Rahm; Anna Sukhanova; Jennifer Ellis; Judy Mouchawar
Journal:  J Genet Couns       Date:  2007-04       Impact factor: 2.537

3.  Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines.

Authors:  Julia Hall; Susan Gray; Roger A'Hern; Susan Shanley; Maggie Watson; Kathryn Kash; Robert Croyle; Rosalind Eeles
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

4.  A model for patient-direct screening and referral for familial cancer risk.

Authors:  Kristin B Niendorf; Melissa A Geller; Rachel Isaksson Vogel; Timothy R Church; Anna Leininger; Angela Bakke; Robert D Madoff
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

5.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

Review 6.  Communication and technology in genetic counseling for familial cancer.

Authors:  H T Lynch; C Snyder; M Stacey; B Olson; S K Peterson; S Buxbaum; T Shaw; P M Lynch
Journal:  Clin Genet       Date:  2013-12-20       Impact factor: 4.438

7.  Case-finding in Fabry disease: experience from the North of England.

Authors:  Paul Brennan; Oliver Parkes
Journal:  J Inherit Metab Dis       Date:  2013-07-05       Impact factor: 4.982

8.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

9.  KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.

Authors:  Jennifer Webster; Tia L Kauffman; Heather Spencer Feigelson; Pamala A Pawloski; Adedayo A Onitilo; Arnold L Potosky; Deanna Cross; Paul R Meier; Anousheh S Mirabedi; Thomas Delate; Yihe Daida; Andrew E Williams; Gwen L Alexander; Catherine A McCarty; Stacey Honda; Lawrence H Kushi; Katrina A B Goddard
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-11-15       Impact factor: 4.254

10.  Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.

Authors:  Kelly A Metcalfe; Isabel Fan; John McLaughlin; Harvey A Risch; Barry Rosen; Joan Murphy; Linda Bradley; Susan Armel; Ping Sun; Steven A Narod
Journal:  Gynecol Oncol       Date:  2008-11-20       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.